Evidence presented at AAIC 2026 shows blood tests can help doctors evaluate mild cognitive impairment with about 90% diagnostic accuracy after results. Mild cognitive impairment means measurable memory or thinking change without loss of daily function, and the findings support questions to shape a diagnostic plan.
The results do not make every test equal. Accuracy, symptoms, and insurance coverage still shape next steps. A planned talk with a doctor can turn a test result into clear action.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the new studies show?
- Who can consider testing now?
- What makes a diagnostic plan reliable?
- Which questions help at the visit?
What did the new studies show?
The Alzheimer's Association reports a Swedish real-world study of 1,310 patients and 165 physicians tested C2N's PrecivityAD2 blood test for amyloid-beta plus phosphorylated tau AAIC 2026 overview. Accuracy improved in both primary-care and specialist settings after doctors received results. The Association reports primary-care doctors and specialists each reached about 90% diagnostic accuracy after results.
That allowed family doctors to diagnose almost as accurately as specialists and rule out Alzheimer's more confidently after a negative result. The Alzheimer's Association, via PR Newswire, followed nearly 2,700 cognitively healthy older adults for up to 10 years study announcement. Elevated blood p-tau217 predicted later impairment at 2, 5 and 10 years, with very high levels tied to substantially higher decade risk.
Who can consider testing now?
Under the Alzheimer's Association guideline, testing is meant for people with objective impairment such as MCI seen in specialized care. A doctor should order the test only when memory or thinking problems are already present. A National Library of Medicine entry notes FDA cleared Fujirebio's Lumipulse G test on May 16, 2025 approval record.
It measures pTau217/Beta-Amyloid 1-42 plasma ratio for amyloid assessment in symptomatic adults 55 and older. VA-News reports two more clearances in August 2026 brought the total to four. They included C2N PrecivityAD2 for symptomatic adults as young as 40 and the Roche/Eli Lilly Elecsys pTau217 plasma test.
What makes a diagnostic plan reliable?
The Alzheimer's Association 2025 guideline sets a clear bar guideline text. Tests with at least 90% sensitivity and 90% specificity can substitute for amyloid PET or CSF testing. Tests with 90% sensitivity but only 75% specificity are triage-only. The same guideline finds many commercial tests do not meet those bars.
Under the same guideline, testing is for objective impairment such as MCI seen in specialized care. A positive triage result still needs PET or CSF confirmation. Coverage adds another decision point. The Alzheimer's Association notes tests are not universally covered by Medicare or commercial insurance. Coverage may affect need for confirmatory testing or treatment-eligibility workup.
Which questions help at the visit?
Bring a short history of onset, daily function, drugs, sleep, mood, and family history. Ask which test the clinic uses and what its result can and cannot decide.
Write answers down during the visit and keep a copy with test name and date. Ask what symptom change should prompt an earlier return and what the next workup would add.
- What is my exact cognitive diagnosis today and what supports it?
- Which blood test do you use, and does it meet substitute or triage accuracy?
- Will a positive result need PET or CSF confirmation in my case?
- What does a negative result rule out, and what follow-up do I need?
- Is the test covered for me, and will coverage affect confirmatory or treatment-eligibility steps?
You Might Also Like
- The AAIC 2026 Swedish Real-World Blood Test Study: Questions People With Mild Cognitive Impairment Can Bring to a Clinician
- AAIC 2026 Primary Care Alzheimer’s Blood Test Findings: Questions People With Mild Cognitive Impairment Can Bring to a Clinician
- Vitamin Supplements in the 2026 WHO Dementia Guideline: Questions Adults Over 65 Can Discuss With a Clinician
